SOLVD
Studies of Left Ventricular Dysfunction — Treatment Trial
Doente / População Intervenção / Exposição Comparação Desfecho
In 2,569 patients with symptomatic heart failure and EF ≤ 0.35, enalapril reduced all-cause mortality compared with placebo.
N
2569
Desenho
Double-blind placebo-controlled RCT
Desfecho
All-cause mortality
Relevância
2
Resultado35.2% with enalapril vs 39.7% with placebo (16% relative risk reduction, 95% CI 5-26; P=0.0036) over mean 41.4 months; HF hospitalisations also reduced.
SOLVD Investigators (Yusuf S, et al). N Engl J Med. 1991;325(5):293-302. 10.1056/NEJM199108013250501
Discussão e crítica
Predates modern background therapy (beta-blockers, MRAs, devices), so absolute benefit differs today. Foundational trial establishing ACE inhibitors as cornerstone therapy for symptomatic HFrEF.